21 completed, 7 terminated, 4 recruiting, 4 unknown. 37 Phase 2, 5 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 37 | Completed 21, Terminated 7, Recruiting 4, Unknown 4, Withdrawn 1 |
| Phase 1 | 5 | Completed 3, Recruiting 1, Unknown 1 |
| Phase 3 | 2 | Recruiting 1, Unknown 1 |
Follow Interstitial Cystitis: new trials by email Literature Review of Interstitial Cystitis trials Research Report on Interstitial Cystitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety, Efficacy, and Frequency of Administration of VNX001 in the Treatment of Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS) VNX001 - Interstitial Cystitis, Bladder Pain Syndrome | Phase 2 | Recruiting | Vaneltix Pharma, Inc. | 50 | 2024-12-13 | 2026-01-22 |
| Amniotic Membrane Therapy for Interstitial Cystitis/Painful Bladder Syndrome Clarix Flo, Placebo - Interstitial Cystitis, Painful Bladder Syndrome | Phase 2 / Phase 3 | Recruiting | David Sheyn | 100 | 2024-07-24 | 2026-09-04 |
| Assessing the Effectiveness and Safety of Interferon Bladder Infusion for the Treatment of Interstitial Cystitis Interferon, Sodium Hyaluronate, Sodium Chloride Injection - Interstitial Cystitis | Phase 2 / Phase 3 | Unknown | West China Hospital | 129 | 2023-10-15 | 2023-09-15 |
| Safety and Efficacy Study of VNX001 Compared to Its Individual Components (Lidocaine and Heparin) or Placebo in Subjects With IC/BPS VNX001, Placebo, Lidocaine - Interstitial Cystitis, Bladder Pain Syndrome | Phase 2 | Recruiting | Vaneltix Pharma, Inc. | 120 | 2023-05-22 | 2026-01-22 |
| A Phase 2 Study of IW-3300 for the Treatment of Bladder Pain in Subjects With Interstitial Cystitis/Bladder Pain Syndrome IW-3300 rectal foam, Placebo - Interstitial Cystitis, Bladder Pain Syndrome | Phase 2 | Terminated | Ironwood Pharmaceuticals, Inc. | 98 | 2023-03-28 | 2025-02-28 |
| Peppermint Oil for the Treatment of Interstitial Cystitis / Bladder Pain Syndrome Peppermint oil, Coconut Oil - Interstitial Cystitis | Phase 1 / Phase 2 | Recruiting | University of Louisville | 100 | 2021-09-15 | 2022-08-22 |
| Efficacy and Safety of Low Energy Shock Wave Plus BotulinumToxin A in Treating Patients With Interstitial Cystitis BOTOX 100U in normal saline, Normal saline - Interstitial Cystitis | Phase 2 | Unknown | Buddhist Tzu Chi General Hospital | 75 | 2021-05-18 | 2022-03-25 |
| A Study to Test if Fremanezumab Reduces Pain in Patients With Interstitial Cystitis-Bladder Pain Syndrome fremanezumab - Interstitial Cystitis | Phase 2 | Withdrawn | Teva Branded Pharmaceutical Products R&D, Inc. | 2020-10-15 | 2021-11-09 | |
| Low-dose Naltrexone for Bladder Pain Syndrome Naltrexone, Placebo - Bladder Pain Syndrome, Interstitial Cystitis | Phase 2 | Terminated | Stanford University | 29 | 2020-10-08 | 2026-07-10 |
| The Female Microbiome in Patients Undergoing Bladder Instillation Therapy Heparin & Alkalinized Lidocaine Bladder Instillation - Interstitial Cystitis, Bladder Pain Syndrome | Phase 2 | Completed | Walter Reed National Military Medical Center | 29 | 2020-10-01 | 2024-08-14 |
| Bladder Instillations Versus Onabotulinumtoxin A for Treatment of Interstitial Cystitis/Bladder Pain Syndrome Heparin & Alkalinized Lidocaine Bladder Instillation, Onabotulinum Toxin A - Interstitial Cystitis, Bladder Pain Syndrome | Phase 2 | Completed | Walter Reed National Military Medical Center | 58 | 2020-09-15 | 2023-10-12 |
| PK and Safety of SI-722 in IC/BPS SI-722, Placebo - Interstitial Cystitis, Bladder Pain Syndrome | Phase 1 / Phase 2 | Completed | Seikagaku Corporation | 33 | 2020-03-30 | 2023-12-29 |
| Vestibulodynia: Understanding Pathophysiology and Determining Appropriate Treatments 5% lidocaine/5 mg/ml 0.02% estradiol compound cream, Nortriptyline, Placebo cream - Vestibulodynia, Temporomandibular Disorder | Phase 2 | Completed | Duke University | 209 | 2019-11-04 | 2026-03-19 |
| Platelet Enriched Plasma for Treatment of Interstitial Cystitis platelet enriched plasma - Interstitial Cystitis, Bladder Pain Syndrome | Phase 1 / Phase 2 | Unknown | Mansoura University | 33 | 2019-03-20 | 2019-10-08 |
| A Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects With Bladder Pain Syndrome/Interstitial Cystitis ASP6294, Placebo - Bladder Pain Syndrome, Interstitial Cystitis | Phase 2 | Completed | Astellas Pharma Europe B.V. | 119 | 2017-09-28 | 2024-10-31 |
| Engage 24: Evaluation of the Safety and Effectiveness of URG101 in Subjects With Interstitial Cystitis/Bladder Pain Syndrome URG101, Placebo, Lidocaine - Interstitial Cystitis, Bladder Pain Syndrome | Phase 2 | Terminated | Urigen | 91 | 2015-09-01 | 2026-02-03 |
| Evaluation of Intravesical LP08 in Patients With Interstitial Cystitis/Painful Bladder Syndrome LP-08 80mg, Normal saline, LP-08 20mg - Interstitial Cystitis | Phase 2 | Completed | Lipella Pharmaceuticals, Inc. | 21 | 2015-07-21 | 2018-11-01 |
| Intravesical Instillation of Liposome Encapsulated Botulinum Toxin A (Lipotoxin) in Treatment of Interstitial Cystitis Liposome encapsulated BoNT-A, BOTOX 200U in normal saline, Normal saline - Interstitial Cystitis | Phase 2 | Completed | Buddhist Tzu Chi General Hospital | 90 | 2014-09-01 | 2017-03-09 |
| Efficacy and Safety of Intravesical Instillations of Botulinum Toxin in TC-3 Gel in IC Patients TC-3 Gel mixed with Botox (BTX) - Interstitial Cystitis, IC | Phase 1 / Phase 2 | Completed | UroGen Pharma Ltd. | 15 | 2013-11-01 | 2016-04-12 |
| Cyclosporine in Interstitial Cystitis: Efficacy, Safety and Mechanism of Action Cyclosporine - Interstitial Cystitis | Phase 2 | Completed | The Cleveland Clinic | 26 | 2013-11-01 | 2017-04-19 |
Showing 20 of 37. Sign in to see all of them.
Cystitis, Interstitial (37) · Pelvic Pain (3) · Pain (2) · Urinary Bladder Diseases (2) · Back Pain (1) · Chronic Pain (1) · Communicable Diseases (1) · Endometriosis (1) · Fatigue Syndrome, Chronic (1) · Fibromyalgia (1) · Irritable Bowel Syndrome (1) · Migraine Disorders (1) · Rare Diseases (1) · Temporomandibular Joint Disorders (1) · Tension-Type Headache (1)
Cystitis (37) · Female Urogenital Diseases (37) · Female Urogenital Diseases and Pregnancy Complications (37) · Male Urogenital Diseases (37) · Urologic Diseases (37) · Urogenital Diseases (36) · Urinary Bladder Diseases (35) · Pathological Conditions, Signs and Symptoms (7) · Neurologic Manifestations (5) · Signs and Symptoms (5) · Disease Attributes (3) · Pain (3) · Pathologic Processes (3) · Genital Diseases (2) · Genital Diseases, Female (2)
Heparin (4) · Botulinum Toxins, Type A (3) · Saline Solution (3) · Sodium Chloride (3) · Cystoscopy (2) · Lidocaine (2) · 4-(4-(aminomethyl)-7a-methyl-1-methylideneoctahydro-1H-inden-5-yl)-3-(hydroxymethyl)-4-methylcyclohexan-1-ol (1) · 4-(6-acetyl-3-(3-(4-acetyl-3-hydroxy-2-propylphenylthio)propoxy)-2-propylphenoxy)butyric acid (1) · BID protein, human (1) · Buffers (1) · Capsaicin (1) · Chondroitin Sulfates (1) · Coconut Oil (1) · Cyclosporine (1) · Dimethyl Sulfoxide (1)
Buddhist Tzu Chi General Hospital (3) · Urigen (3) · Allergan (2) · Vaneltix Pharma, Inc. (2) · Walter Reed National Military Medical Center (2) · Watson Pharmaceuticals (2) · Aquinox Pharmaceuticals (Canada) Inc. (1) · Astellas Pharma Europe B.V. (1) · Corewell Health East (1) · David Sheyn (1) · Duke University (1) · ICOS Corporation (1) · Ironwood Pharmaceuticals, Inc. (1) · Kenneth Peters, MD (1) · Lipella Pharmaceuticals, Inc. (1)
United States (25) · Canada (6) · Germany (3) · Taiwan (3) · Czechia (2) · Hungary (2) · Poland (2) · Russia (2) · United Kingdom (2) · Belgium (1) · Denmark (1) · Egypt (1) · Finland (1) · France (1) · Israel (1)
Hann-Chorng Kuo, M.D. (3) · C. Lowell Parsons, MD (2) · Curtis Nickel, MD (2) · Ahmed El Hefnawy, Msc, MD (1) · Amnon Zisman, MD (1) · Andrea Nackley, PhD (1) · Craig V Comiter, MD (1) · Daniel Shoskes, M.D. (1) · David Sheyn, MD (1) · Eva K Welch, MD MS (1) · Hugh Flood (1) · Jeff Proctor, M.D. (1) · Jennifer M Hah, MD, MS (1) · Jerzy Gajewski, MD, FRCSC (1) · Kenneth Peters, M.D. (1)
PMID 32734597, PMID 22818144, PMID 36269028, PMID 38587846, PMID 38768800, PMID 42857927
2009 (1), 2016 (1), R01DK049524 (1), R01HD096331 (1)